Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 788

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Prof Anton Hagenbeek comments on Dr Ekaterina Chelysheva's session on pregnancy outcomes in patients with chronic myeloid leukaemia (CML) at the 2019 European Hematology Association (EHA) Annual Meeting.

Dr Chelysheva's study did an international survey of pregnant CML patients, finding that the most frequent outcome was labor with a healthy baby.

Prof Hagenbeek remarks that these findings have been made possible by advancements in tyrosine kinase inhibitor treatments, which not only help women to live longer but also do not affect their fertility like past treatments.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation